Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Extracellular Vesicles And Lung Cancer Metastasis

  Lung cancer metastasis remains a major cause of cancer-related illness because tumour cells can spread before a primary lesion causes obvious symptoms. Research into extracellular vesicles (EVs) has opened a new view of this process: tiny membrane-bound particles released by cancer cells may carry molecular instructions that prepare distant organs, alter immune responses and support the growth of secondary tumours.

  For respiratory physicians, thoracic oncologists and translational researchers, EVs are important because they connect tumour biology with practical possibilities such as liquid biopsy, treatment monitoring and personalised risk assessment. Their relevance sits alongside familiar clinical concerns, including smoking-related disease, occupational exposure, chronic lung conditions and the difficulty of distinguishing infection from malignancy during early investigation.

  What Extracellular Vesicles Carry

  Extracellular vesicles include exosomes and larger microvesicles released into the blood, airway fluid and tissue environment. They contain proteins, lipids, messenger RNA, microRNA and fragments of DNA. Because their lipid membrane protects this cargo, EVs can travel through circulation and deliver biological signals to other cells.

  In lung cancer, vesicles may carry oncogenic molecules that influence cell survival, angiogenesis and resistance to therapy. Their contents vary according to tumour type, genetic profile and environmental conditions. Hypoxia, inflammation and exposure to treatment can all change the quantity and molecular composition of vesicles released by malignant cells.

  How Vesicles Support Metastatic Spread

  Metastasis involves several linked steps: local invasion, entry into blood or lymphatic vessels, survival during circulation, exit into a distant organ and successful colonisation. EVs can assist at multiple points. They may weaken surrounding tissue barriers, stimulate blood-vessel formation and alter adhesion molecules that help tumour cells migrate.

  A key concept is the pre-metastatic niche. Before cancer cells arrive, tumour-derived vesicles can reach organs such as the brain, liver or bone and modify resident cells. They may recruit suppressive immune cells, reshape extracellular matrix proteins and make the local environment more favourable to tumour implantation. This helps explain why metastasis is an active biological process rather than simple cellular dispersal.

  Immune Escape And The Tumour Microenvironment

  The lung contains a complex immune landscape involving macrophages, dendritic cells, lymphocytes and epithelial cells. Cancer-derived EVs can interfere with immune surveillance by encouraging macrophages to adopt tumour-supporting behaviour or by reducing the activity of natural killer cells and cytotoxic T cells. Vesicles may also transport signals that increase checkpoint ligand expression.

  EVs influence fibroblasts and endothelial cells in the tumour microenvironment as well. These changes can promote fibrosis, vascular permeability and new vessel formation. The resulting environment gives malignant cells access to nutrients and protection from immune attack, while helping establish the conditions required for metastatic growth.

  Liquid Biopsy And Biomarker Potential

  Because EVs circulate in accessible body fluids, they are being studied as a form of liquid biopsy. Blood-based vesicle analysis could potentially identify tumour-associated mutations, microRNA patterns or protein signatures without requiring repeated tissue sampling. This would be valuable when a lung lesion is difficult to reach or when metastatic disease changes over time.

  However, clinical use still requires careful standardisation. Laboratories differ in how they isolate, count and characterise EVs, while samples contain vesicles from platelets, immune cells and normal tissue. Large prospective studies must establish whether a particular signature can reliably predict metastasis, treatment response or recurrence in real-world patients.

  Treatment And Diagnostic Implications

  EVs may become therapeutic targets as well as biomarkers. Researchers are investigating ways to block vesicle release, prevent uptake by recipient cells or interrupt the molecular cargo they deliver. Engineered vesicles are also being explored as carriers for drugs, small interfering RNA and immune-modulating compounds, although safety, manufacturing and delivery remain substantial issues.

  Respiratory symptoms can have several causes, especially in patients with chronic lung disease. Fever, cough and infiltrates may reflect infection, inflammation or malignancy, so biomarker research needs to fit into broader clinical reasoning. Discussion of procalcitonin guidance illustrates how additional biological signals may help clinicians make more targeted decisions while a cancer diagnosis is being clarified.

  Relevance To Australian Respiratory Care

  Australia has distinctive settings for lung cancer research and care. Patients from regional and remote communities may travel long distances to Brisbane, Sydney, Melbourne, Perth or Adelaide for bronchoscopy, molecular testing and oncology review. A blood-based EV assay could eventually reduce repeat travel, provided samples can be collected, transported and processed consistently.

  The country also has important exposure patterns, from smoking and urban air pollution to mining-related occupational risks and prolonged sun-related outdoor work that may affect general health. In places such as Western Australia and Queensland, collaboration between metropolitan centres and rural hospitals will be essential for validating biomarkers across different populations.

  Australian healthcare operates through a mix of public hospitals, private providers and Medicare-supported services. Any EV test would need evidence of clinical benefit, an affordable laboratory pathway and a clear reimbursement model. Australian clinicians also tend to value practical, evidence-based tools that fit multidisciplinary meetings rather than adding an isolated result to an already crowded workflow.

  Potential EV Application	Possible Clinical Value	Main Barrier
  Early detection	Signals from tumour-derived vesicles could support assessment of suspicious lesions	Low abundance and overlap with non-cancer conditions
  Metastatic risk assessment	Molecular cargo may indicate a tendency to spread	Need for large, diverse validation cohorts
  Treatment monitoring	Changes in EV cargo could reflect response or resistance	Sampling and laboratory methods are not uniform
  Drug delivery	Engineered vesicles might transport targeted therapies	Manufacturing, safety and quality control

  What The Evidence Should Establish

  The strongest future studies will link EV measurements with imaging, pathology, genomic profiling and patient outcomes. They should include people from metropolitan, regional and remote Australia, as well as different lung cancer subtypes and stages. Consistent definitions for exosomes, microvesicles, isolation methods and reporting standards will make findings easier to compare.

  Extracellular vesicles offer a compelling explanation for how lung tumours communicate with distant organs and reshape the immune and tissue environment before metastases become visible. Their greatest promise is the possibility of earlier warning and more individualised treatment, but reliable clinical value will depend on rigorous validation. The key point to remember is that EVs are both messengers of metastatic disease and potential tools for detecting, tracking and eventually interrupting its spread.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)